LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Novartis AG

Închisă

109.54 1.09

Rezumat

Modificarea prețului

24h

Curent

Minim

108.06

Maxim

109.58

Indicatori cheie

By Trading Economics

Venit

786M

3.6B

Vânzări

62M

14B

P/E

Medie Sector

17.077

56.602

EPS

2.28

Randament dividend

3.67

Marjă de profit

26.476

Angajați

75,883

EBITDA

643M

5.8B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-1.35% downside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.67%

2.45%

Statistici piață

By TradingEconomics

Capitalizare de piață

-765M

217B

Deschiderea anterioară

108.45

Închiderea anterioară

109.54

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Novartis AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mai 2025, 09:36 UTC

Principalele dinamici ale pieței

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 apr. 2025, 16:35 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 apr. 2025, 11:55 UTC

Achiziții, Fuziuni, Preluări

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 apr. 2025, 11:54 UTC

Achiziții, Fuziuni, Preluări

Novartis to Acquire Regulus in $1.7 Billion Deal

29 apr. 2025, 07:09 UTC

Câștiguri

Novartis Lifts Guidance After Profit, Sales Top Views -- Update

29 apr. 2025, 05:36 UTC

Câștiguri

Novartis Lifts Guidance After Profit, Sales Top Views

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

30 apr. 2025, 11:40 UTC

Achiziții, Fuziuni, Preluări

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 apr. 2025, 11:39 UTC

Achiziții, Fuziuni, Preluări

Novartis to Acquire Regulus in $1.7B Deal

30 apr. 2025, 11:16 UTC

Achiziții, Fuziuni, Preluări

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 apr. 2025, 11:15 UTC

Achiziții, Fuziuni, Preluări

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 apr. 2025, 11:14 UTC

Achiziții, Fuziuni, Preluări

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 apr. 2025, 11:13 UTC

Achiziții, Fuziuni, Preluări

Novartis to Buy Regulus Therapeutics

29 apr. 2025, 12:34 UTC

Market Talk
Câștiguri

Novartis Solid Result Shifts Investor Focus to 2H -- Market Talk

29 apr. 2025, 11:54 UTC

Market Talk
Câștiguri

Correction to Novartis Market Talk

29 apr. 2025, 11:47 UTC

Market Talk
Câștiguri

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

29 apr. 2025, 10:42 UTC

Market Talk
Câștiguri

Novartis Surprises With Another Beat & Raise -- Market Talk

29 apr. 2025, 10:16 UTC

Market Talk
Câștiguri

Novartis's Guidance Lift Reflects Strong Sales -- Market Talk

29 apr. 2025, 05:06 UTC

Câștiguri

Novartis Had Seen Core Operating Profit to Grow at High Single to Low Double-Digit in 2025 at Constant Currencies

29 apr. 2025, 05:06 UTC

Câștiguri

Novartis Expects Core Operating Profit to Grow Low Double-Digit in 2025 at Constant Currencies

29 apr. 2025, 05:05 UTC

Câștiguri

Novartis Had Seen Sales Grow Mid- to High-Single Digit in 2025 at Constant Currencies

29 apr. 2025, 05:04 UTC

Câștiguri

Novartis Expects Sales to Grow High Single Digit in 2025 at Constant Currencies

29 apr. 2025, 05:02 UTC

Câștiguri

Novartis Raises 2025 View

29 apr. 2025, 05:02 UTC

Câștiguri

Analysts Had Seen Novartis 1Q Rev $13.00B

29 apr. 2025, 05:02 UTC

Câștiguri

Novartis 1Q Rev $13.23B

29 apr. 2025, 05:01 UTC

Câștiguri

Analysts Had Seen Novartis 1Q Core Operating Profit EUR5.22B

29 apr. 2025, 05:01 UTC

Câștiguri

Novartis 1Q Core Operating Profit EUR5.575B

29 apr. 2025, 05:00 UTC

Câștiguri

Novartis AG 1Q Adj EPS $2.28

29 apr. 2025, 05:00 UTC

Câștiguri

Novartis AG 1Q EPS $1.83

Comparație

Modificare preț

Novartis AG Așteptări

Obiectiv de preț

By TipRanks

-1.35% jos

Prognoză pe 12 luni

Medie 107 USD  -1.35%

Maxim 116 USD

Minim 88 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovartis AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

2

Cumpărare

2

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 112.63Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.